Line 44: |
Line 44: |
| |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive |
| |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) |
− | | | + | |Complete |
| |Date page was created | | |Date page was created |
| | | | | |
Line 51: |
Line 51: |
| |Chronic Neutrophilic Leukemia (CNL) | | |Chronic Neutrophilic Leukemia (CNL) |
| |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally |
− | | | + | |Complete |
| |Date page was created | | |Date page was created |
| | | | | |
Line 58: |
Line 58: |
| |Chronic Eosinophilic Leukemia, Not Otherwise Specified | | |Chronic Eosinophilic Leukemia, Not Otherwise Specified |
| |Chelsea D. Kramish; Daynna J.Wolff | | |Chelsea D. Kramish; Daynna J.Wolff |
− | | | + | |complete/pending faculty review |
| | | | | |
| | | | | |
Line 65: |
Line 65: |
| |Polycythemia Vera (PV) | | |Polycythemia Vera (PV) |
| |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center |
− | | | + | |Complete |
| | | | | |
| | | | | |
Line 72: |
Line 72: |
| |Essential Thrombocythemia (ET) | | |Essential Thrombocythemia (ET) |
| |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN |
− | | | + | |Complete |
| | | | | |
| | | | | |
| |- | | |- |
− | |Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| || | + | |Primary myelofibrosis||Disease|| || || || || ||FQR|| || |
− | | | + | |Primary Myelofibrosis (PMF) |
− | | | + | |T. Niroshi Senaratne, UCLA |
− | | | + | |Complete |
| |8/4/2020 before submission<br /> | | |8/4/2020 before submission<br /> |
| | | | | |